Diaceutics (LON:DXRX) Releases Earnings Results

Diaceutics (LON:DXRX) issued its quarterly earnings results on Tuesday. The company reported GBX (3.27) EPS for the quarter, Digital Look Earnings reports. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%.

Diaceutics Price Performance

Shares of LON:DXRX traded up GBX 16 on Tuesday, hitting GBX 186. The company’s stock had a trading volume of 1,307,491 shares, compared to its average volume of 202,378. The company has a 50-day simple moving average of GBX 145.09 and a 200 day simple moving average of GBX 150.64. The company has a market capitalization of £157.84 million, a PE ratio of 1,690.91 and a beta of 0.88. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92. Diaceutics has a 1 year low of GBX 125 and a 1 year high of GBX 186.90.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group restated a “buy” rating and issued a GBX 215 price objective on shares of Diaceutics in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Diaceutics presently has an average rating of “Buy” and an average price target of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.